Ropeginterferon Alfa-2B
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ropeginterferon alfa-2b: From Polycythaemia Vera to Laubry-Pezzi Syndrome
One-Sentence Summary
Ropeginterferon alfa-2b is a long-acting (monopegylated) interferon originally used to treat polycythaemia vera, a chronic blood cancer of the myeloproliferative family. The TxGNN model predicts it may be effective for Laubry-Pezzi syndrome (a ventricular septal defect with aortic regurgitation), but no clinical trials and no relevant publications support this prediction, so it should be treated as a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Polycythaemia vera (acquired); the Singapore licence record contains no indication text, so this comes from the knowledge-graph indication data |
| Predicted New Indication | Laubry-Pezzi syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ropeginterferon alfa-2b is an immunomodulatory and antiproliferative interferon used in myeloproliferative neoplasms. Its efficacy in polycythaemia vera is established, and it is thought to act by suppressing the abnormal JAK2-mutated blood-cell clone.
Laubry-Pezzi syndrome is a structural heart defect (ventricular septal defect with aortic regurgitation). It is not a blood cancer and has no known interferon-responsive pathway. The review found no plausible mechanistic link between the drug and this condition. The high TxGNN score most likely reflects a knowledge-graph artifact, such as proximity among related nodes, rather than a real biological rationale.
The other nine top-ranked predictions are also structural or congenital conditions, such as septal aneurysm, Pierre Robin syndrome, chromosomal deletions, orofacial clefting and pulmonary valve disease. Each has a similar lack of mechanistic support. This pattern suggests a systematic model artifact rather than a true repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the predicted indication, Laubry-Pezzi syndrome.
The data compiled for this report did link five publications to a lower-ranked prediction (disorder of fucoglycosan synthesis). All of them concern polycythaemia vera, the drug's existing indication, so they do not support any new use. They are shown below only as background for the original indication.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33476571 | 2021 | RCT | The Lancet Haematology | Low-PV study: ropeginterferon alfa-2b added to phlebotomy compared with phlebotomy alone in low-risk polycythaemia vera (phase 2) |
| 42566639 | 2026 | Systematic review/Meta-analysis | Medicine | Efficacy and safety of ropeginterferon alfa-2b versus hydroxyurea and phlebotomy in polycythaemia vera |
| 41999414 | 2026 | Review | Annals of Hematology | Modern multidisciplinary care in polycythaemia vera |
| 32814349 | 2021 | Cohort | Blood | Germline genetic factors influence response to interferon-α in polycythaemia vera (PROUD-PV and CONTINUATION-PV, 122 patients) |
| 40770048 | 2025 | Cohort | Blood Cancer Journal | Neutrophil-to-lymphocyte ratio as a surrogate for JAK2V617F suppression and event-free survival in polycythaemia vera |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17014P | Besremi Solution for Injection in Prefilled Syringe 500 micrograms/mL (PharmaEssentia Corporation, Taichung Plant) | Injection, solution | Not stated in the licence record compiled |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy / cytokine (antiproliferative interferon); not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; at minimum, blood counts and liver function are usually monitored with interferon therapy |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
One caution comes from the review of the predictions: interferon-alpha therapy warrants care in patients with cardiovascular disease. This matters because the top predicted indications are cardiac conditions.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials or relevant publications, and no biological link between an antiproliferative interferon and a structural heart defect. This is evidence level L5.
To proceed, the following is needed:
- A documented mechanistic hypothesis, which requires mechanism of action data for the drug
- Any preclinical or clinical evidence specific to Laubry-Pezzi syndrome
- The Singapore package insert (warnings and contraindications), which is needed before any safety screening
- A check of whether the high scores for structural and congenital conditions reflect a model artifact
- Possibly a focus on its established indication, polycythaemia vera, where the evidence is much stronger
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.